Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Exclusion Criteria

• •* AEG Type III: subcardial gastric carcinoma which infiltrates the esophagogastric junction and distal esophagus from below
• •Patients must have received and progressed on one and only one line of prior systemic therapy for esophagus or esophagogastric cancer; this could have included one regimen for metastatic disease, or one regimen with radiotherapy for initially locally advanced disease; prior radiation therapy is permitted
• •* If patients progress or recur within 6 months of neoadjuvant/adjuvant therapy, this will be considered one line of therapy; for patients progressing or recurring more than 6 months after neoadjuvant/adjuvant therapy, they will need to receive one line of therapy for recurrent disease to be eligible
• •* If patients receive one regimen in which a chemotherapy agent is dropped for toxicity without progression, this treatment will be considered one line of therapy; however, substitution or addition of a new agent will be considered a second line of therapy
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• •Leukocytes \> 3,000/mcL
• •Absolute neutrophil count \>= 1,500/mcL
• •Hemoglobin \>= 9 g/dL
• •Platelets \>= 100,000/mcL
• •Total bilirubin =\< institutional upper limit of normal (ULN)
• •Aspartate transaminase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine transaminase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 X institutional ULN
• •Creatinine =\< 1.5 X institutional ULN or creatinine clearance \>= 60 mL/min/1.73m\^2 for patients with creatinine levels above institutional normal
• •Patients must have fasting serum glucose =\< 160 mg/dL (8.8 mmol/L) or =\< ULN, and hemoglobin A1C =\< 7% (0.07 International System of Units \[SI units\]) within 14 days of registration; if baseline nonfasting glucose =\< 160 mg/dL (8.8 mmol/L), fasting glucose measurement is not required
• •Registration no fewer than 28 days from last chemotherapy
• •A "currently active" second malignancy other than non-melanoma skin cancers are not to be registered; patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse
• •Patients have received prior taxane or anti-insulin growth factor receptor (IGFR) therapy
• •Patients must not have any of the following conditions:
• •* Poorly controlled diabetes mellitus; patients with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range (fasting glucose =\< 160 mg/dL \[8.8 mmol/L\] or below the ULN and hemoglobin A1C =\< 7% \[0.07 SI units\]) and that they are on a stable dietary or therapeutic regimen for this condition
• •* Recent major surgery, hormonal therapy (other than replacement) or chemotherapy, within 4 weeks prior to entering the study or those who have not recovered from adverse events
• •* History of allergic reactions attributed to compounds of similar chemical or biologic composition to cixutumumab (IMC-A12)
• •* Psychiatric illness that would prevent the patient from giving informed consent
• •Medical conditions such as active/uncontrolled infection (including HIV) or cardiac disease that would make this protocol unreasonably hazardous for the patient in the opinion of the treating physician; cardiac disease may include uncontrolled high blood pressure, unstable angina, or serious uncontrolled cardiac arrhythmia